Newell M, Harris M, Moyle G, Smith D, Clarbour J, Gazzard B; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 242 (abstract no. M.B.P.122).
St. Stephen's Hospital, Chelsea, London SW10 9TH England
OBJECTIVE: To compare the efficacy and safety of foscarnet (F.) and ganciclovir (G.) in the treatment of CMV retinitis. METHODS: Fourteen patients over 6 months with CMV retinitis were given either a 3 week induction course of G. (5mg/kg/b.d. I.V.-6 patients) or F. (approx 200mg/kg/d. I.V.-8 patients) followed by maintenance therapy 5 days a week (F. 130mg/kg/d., G. 5mg/kg/d. I.V.). Ophthalmological response and any adverse reactions were monitored. RESULTS: A. Acute treatment: All 6 patients on G. completed the course uninterrupted without adverse effect and showed some visual improvement. Five out of 8 patients on F. also completed the course uninterrupted but in 2 a rise in serum creatinine resulted in a dose reduction or interruption. Five patients showed some visual improvement but 3 had continuing active disease one of which was switched to G. B. Maintenance: Six patients on each drug, average duration for F. 11 weeks (range 2 - 19 weeks), for G. 14 weeks (range 4 - 26 weeks). Five patients on F. developed a raised creatinine resulting in dose cessation(1), reduction(1) or interruption(2). In only 1 has disease remained quiescent and 4 patients have died. Three of 6 patients on maintenance G. required dose reduction(1), interruption(1) and change to F.(1) due to neutropenia. Four patients had stable disease, one had a retinal detachment and one relapse requiring dose increase. CONCLUSION: F. and G. have similar efficacy in the treatment of CMV retinitis but F. showed greater toxicity and may be less effective for maintenance.
Publication Types:
Keywords:
- Antiretroviral Therapy, Highly Active
- Cytomegalovirus Retinitis
- Drug Therapy, Combination
- Foscarnet
- Ganciclovir
- Humans
- drug therapy
- therapy
Other ID:
UI: 102176976
From Meeting Abstracts